Protein-based nanotoxicology assessment strategy.

The nanomaterial community calls for standardized in vitro assays to determine nanoparticle toxicity in the effort to reduce the number of in vivo validation experiments. We demonstrate that chip-based protein detection is suitable for assessing toxicity and may complement traditional assays to improve selection of primary hits for subsequent analysis. As nanodrug mimics, we analyzed the effect of transiently transfected siRNAs in MCF7 breast cancer cells and normal MCF12A breast cells, resembling a differential screen. As a measure of cytotoxicity, we determined cell viability as well as protein expression of glyceraldehyde-3-phosphate dehydrogenase, transferrin receptor, and the proliferation marker Ki67. The evaluation of cell lethality and protein expression unraveled cellular effects overseen by one method alone.

[1]  A Worth,et al.  Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST , 2015, Nanotoxicology.

[2]  Maria Dusinska,et al.  Suitability of human and mammalian cells of different origin for the assessment of genotoxicity of metal and polymeric engineered nanoparticles , 2015, Nanotoxicology.

[3]  Maria Dusinska,et al.  Iron oxide nanoparticle toxicity testing using high-throughput analysis and high-content imaging , 2015, Nanotoxicology.

[4]  A. Moore,et al.  Sequence‐dependent combination therapy with doxorubicin and a survivin‐specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma , 2014, International journal of cancer.

[5]  Maria Dusinska,et al.  NanoTEST in a Nutshell , 2015, Nanotoxicology.

[6]  Emanuel F Petricoin,et al.  Preparation and Use of Reverse Protein Microarrays , 2014, Current protocols in protein science.

[7]  Jingchun Zhu,et al.  Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report , 2014, Molecular & Cellular Proteomics.

[8]  G. Dai,et al.  Image-guided breast tumor therapy using a small interfering RNA nanodrug. , 2010, Cancer research.

[9]  Xuming He,et al.  Non-parametric quantification of protein lysate arrays , 2007, Bioinform..

[10]  Hugh J. Byrne,et al.  Concern-driven integrated approaches to nanomaterial testing and assessment – report of the NanoSafety Cluster Working Group 10 , 2013, Nanotoxicology.

[11]  Mads Thomassen,et al.  Microarray R-based analysis of complex lysate experiments with MIRACLE , 2014, Bioinform..

[12]  Junnian Zheng,et al.  Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. , 2006, Life sciences.

[13]  M. Hung,et al.  The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines , 2010, Breast cancer : basic and clinical research.

[14]  W. Mark Saltzman,et al.  Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA , 2009, Nature materials.

[15]  Li Zhang,et al.  Serial dilution curve: a new method for analysis of reverse phase protein array data , 2009, Bioinform..

[16]  O. Kepp,et al.  Quantification of cellular viability by automated microscopy and flow cytometry , 2015, Oncotarget.

[17]  Maria Dusinska,et al.  Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests , 2015, Nanotoxicology.

[18]  P. McCue,et al.  Knockdown of Ki-67 by Dicer-Substrate Small Interfering RNA Sensitizes Bladder Cancer Cells to Curcumin-Induced Tumor Inhibition , 2012, PloS one.